strong relationships with influential reporters, venture capitalists, investment bankers and equity analysts.

Services include corporate communications as it fits into an overall investor relations program, management counsel, corporate positioning, pre-IPO public relations and media outreach.

Understanding and meeting the unique needs of each client is paramount to our business philosophy. We work with clients on a day-to-day basis to be aware of evolving needs and adjust our activities accordingly. We also maintain a high level of responsiveness by being available, strategic and dedicated at all times.

Our clients benefit from the undivided attention of a dedicated account team led by Gregory Tiberend, president & CEO of the firm. Every day our team of account professionals will interact with you to exchange ideas, formulate suggestions, develop strategic solutions, bring new opportunities and work diligently to execute.

We strive to recommend the most appropriate communication mix that fits within your corporate goals and budget. We are cost conscious, always accommodate our clients’ needs and offer innovative alternatives to achieve challenging goals.

Headquartered near Herald Square in Midtown Manhattan, Tiberend Strategic Advisors, Inc. serves its clients on a global basis. 

 

Tiberend Strategic Advisors, Inc. (TSAI), formerly known as Richard Lewis Communications, Inc., was founded in 1989 by Richard S. Lewis and Gregory Q. Tiberend.

We are a full-service corporate communications firm specializing in developing strategic communications programs for publicly traded companies as well as for private and emerging growth companies. Our team has developed personalized solutions for clients by providing them with the best possible combination of communications tactics.  We are committed to building long-term, mutually beneficial relationships with select clients.

Our industry focuses are life sciences and financial services communications.  Within the life science sector, we focus on companies ranging from venture-backed early-stage developmental companies to publicly traded companies with approved therapies. We work closely with senior management teams of biotechnology, medical device and diagnostics companies and understand the specific communications challenges of small and mid-cap companies from multiple perspectives.

Since our founding, we have earned an exceptional reputation for credibility, responsiveness, quality execution and delivering results. We do not rest on our laurels and we endeavor daily to maintain the reputation for which we are known.

By consistently monitoring industry trends and the political climate, we are able to identify opportunities for clients and convert them into meaningful results. Clients benefit from our